Skip to content
lifestyle.theglimpse.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ernexa Therapeutics Inc.
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
May 6, 2026
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
April 30, 2026
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
March 31, 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
February 20, 2026
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
February 10, 2026
←
Previous Page
1
2